The defining editing modality for Allogene Therapeutics is allogeneic CAR-T; off-the-shelf T-cell therapy supplies the molecular or delivery context that makes the platform distinctive. Its editing stack links TALEN gene editing for cell therapy to BCMA allogeneic CAR-T research; donor-derived engineered T cells shows how programmable DNA modification is implemented in a specific tissue or therapeutic workflow. CRISPR systems, editing chemistries and therapeutic products remain separate tags; the editing platform of Allogene Therapeutics also includes hematologic malignancy cellular immunotherapy.
A surge of more than 180 companies is driving over 200 CAR-T therapies through the clinical pipeline, with new strategies aiming to overcome resistance and expand beyond cancer.
We use cookies to operate the website and understand site usage and improve your experience
